← Back to Search

Kinase Inhibitor

Ibrutinib plus Ruxolitinib for Lymphoma

Phase 1 & 2
Waitlist Available
Led By David E Spaner, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

This study involves adding the kinase inhibitor Ruxolitinib to Ibrutinib to treat Chronic Lymphocytic Leukemia (CLL).

Eligible Conditions
  • Lymphoma
  • Chronic B-Cell Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
maximum tolerated dose (MTD) of ruxolitinib in combination with Ibrutinib.
Secondary study objectives
ability of Ruxolitinib to increase the depth of response to Ibrutinib
Other study objectives
effect of Ruxolitinib on levels of plasma cytokines and chemokines

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ibrutinib plus RuxolitinibExperimental Treatment2 Interventions
Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
Group II: Ibrutinib aloneActive Control1 Intervention
Patients will continue to take Ibrutinib for the equivalent period of time.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib
FDA approved
Ibrutinib
FDA approved

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,819 Total Patients Enrolled
6 Trials studying Lymphoma
330 Patients Enrolled for Lymphoma
NovartisIndustry Sponsor
1,636 Previous Clinical Trials
2,773,557 Total Patients Enrolled
36 Trials studying Lymphoma
955 Patients Enrolled for Lymphoma
David E Spaner, MDPrincipal InvestigatorSunnybrook Odette Cancer Center
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top